Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is characterized by inflammation of nerve roots and peripheral nerves in conjunction with destruction of myelin sheath of the nerve fibers. Loss or damage of myelin sheath can slowdown or block the nerve signals. CIDP is an auto-immune disorder with a very low prevalence of around 5-7 cases per 100,000 individuals. Males are more likely to get affected by CIDP as compared to females. At times, diagnosing CIDP can be very difficult. However, muscle weakness for more than two months along with symmetric proximal and distal weakness with reduced or absent tendon reflexes are highly suggestive of CIDP. There are various effective treatments available for CIDP which primarily consist of glucocorticoids (steroids) like prednisone, some immunosuppressive drugs, intravenous immunoglobulin, and plasma exchange.
“Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape is provided which includes the disease overview and Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment guidelines. The assessment part of the report embraces, in depth Chronic inflammatory demyelinating polyneuropathy (CIDP) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic inflammatory demyelinating polyneuropathy (CIDP) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic inflammatory demyelinating polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic inflammatory demyelinating polyneuropathy (CIDP).
Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs Chapters
This segment of the Chronic inflammatory demyelinating polyneuropathy (CIDP) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs
HYQVIA: Takeda Pharmaceuticals
Takeda’s lead drug candidate, HYQVIA, is a solution for subcutaneous administration. The drug is being developed for chronic inflammatory demyelinating polyneuropathy disorder. The drug has demonstrated good efficacy and tolerability. It has also been designated with orphan drug status for CIPD. It act as an immunomodulant that reacts with the receptor of targeted cells to up-regulate or down-regulate immune response.
Rozanolixizumab: UCB Biopharma
UCB Biopharma’s “novel” drug molecule Rozanolixizumab is currently being evaluated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The drug is a neonatal Fc receptor antagonist which belong to the class of anti-inflammatories as well as monoclonal antibodies. Rozanolixizumab works by binding with high-affinity to human neonatal Fc receptor (FcRn), selectively inhibiting IgG rescue and recycling.
Further product details are provided in the report……..
Chronic inflammatory demyelinating polyneuropathy (CIDP): Therapeutic Assessment
This segment of the report provides insights about the different Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic inflammatory demyelinating polyneuropathy (CIDP)
There are approx. 10+ key companies which are developing the therapies for Chronic inflammatory demyelinating polyneuropathy (CIDP). The companies which have their Chronic inflammatory demyelinating polyneuropathy (CIDP) drug candidates in the most advanced stage, i.e. phase III include, Takeda Pharmaceuticals.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic inflammatory demyelinating polyneuropathy (CIDP): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs.
Chronic inflammatory demyelinating polyneuropathy (CIDP) Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is characterized by inflammation of nerve roots and peripheral nerves in conjunction with destruction of myelin sheath of the nerve fibers. Loss or damage of myelin sheath can slowdown or block the nerve signals. CIDP is an auto-immune disorder with a very low prevalence of around 5-7 cases per 100,000 individuals. Males are more likely to get affected by CIDP as compared to females. At times, diagnosing CIDP can be very difficult. However, muscle weakness for more than two months along with symmetric proximal and distal weakness with reduced or absent tendon reflexes are highly suggestive of CIDP. There are various effective treatments available for CIDP which primarily consist of glucocorticoids (steroids) like prednisone, some immunosuppressive drugs, intravenous immunoglobulin, and plasma exchange.
“Chronic inflammatory demyelinating polyneuropathy (CIDP) - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape is provided which includes the disease overview and Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment guidelines. The assessment part of the report embraces, in depth Chronic inflammatory demyelinating polyneuropathy (CIDP) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic inflammatory demyelinating polyneuropathy (CIDP) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic inflammatory demyelinating polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic inflammatory demyelinating polyneuropathy (CIDP).
Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs Chapters
This segment of the Chronic inflammatory demyelinating polyneuropathy (CIDP) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs
HYQVIA: Takeda Pharmaceuticals
Takeda’s lead drug candidate, HYQVIA, is a solution for subcutaneous administration. The drug is being developed for chronic inflammatory demyelinating polyneuropathy disorder. The drug has demonstrated good efficacy and tolerability. It has also been designated with orphan drug status for CIPD. It act as an immunomodulant that reacts with the receptor of targeted cells to up-regulate or down-regulate immune response.
Rozanolixizumab: UCB Biopharma
UCB Biopharma’s “novel” drug molecule Rozanolixizumab is currently being evaluated for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). The drug is a neonatal Fc receptor antagonist which belong to the class of anti-inflammatories as well as monoclonal antibodies. Rozanolixizumab works by binding with high-affinity to human neonatal Fc receptor (FcRn), selectively inhibiting IgG rescue and recycling.
Further product details are provided in the report……..
Chronic inflammatory demyelinating polyneuropathy (CIDP): Therapeutic Assessment
This segment of the report provides insights about the different Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Chronic inflammatory demyelinating polyneuropathy (CIDP)
There are approx. 10+ key companies which are developing the therapies for Chronic inflammatory demyelinating polyneuropathy (CIDP). The companies which have their Chronic inflammatory demyelinating polyneuropathy (CIDP) drug candidates in the most advanced stage, i.e. phase III include, Takeda Pharmaceuticals.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic inflammatory demyelinating polyneuropathy (CIDP): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs.
Chronic inflammatory demyelinating polyneuropathy (CIDP) Report Insights
- Chronic inflammatory demyelinating polyneuropathy (CIDP) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs?
- How many Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic inflammatory demyelinating polyneuropathy (CIDP)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic inflammatory demyelinating polyneuropathy (CIDP) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Takeda Pharmaceuticals
- UCB Biopharma
- LFB Biotechnologies
- Argenx
- Octapharma
- HYQVIA
- Rozanolixizumab
- I10E
- Efgartigimod
- NewGam
Introduction
Executive Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic inflammatory demyelinating polyneuropathy (CIDP) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chronic inflammatory demyelinating polyneuropathy (CIDP) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chronic inflammatory demyelinating polyneuropathy (CIDP) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
HYQVIA: Takeda Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Rozanolixizumab: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Companies
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Products
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Unmet Needs
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Market Drivers and Barriers
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Future Perspectives and Conclusion
Chronic inflammatory demyelinating polyneuropathy (CIDP) Analyst Views
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Companies
Appendix
Executive Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic inflammatory demyelinating polyneuropathy (CIDP) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chronic inflammatory demyelinating polyneuropathy (CIDP) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chronic inflammatory demyelinating polyneuropathy (CIDP) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
HYQVIA: Takeda Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Rozanolixizumab: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Companies
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Products
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Unmet Needs
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Market Drivers and Barriers
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Future Perspectives and Conclusion
Chronic inflammatory demyelinating polyneuropathy (CIDP) Analyst Views
Chronic inflammatory demyelinating polyneuropathy (CIDP) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic inflammatory demyelinating polyneuropathy (CIDP)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic inflammatory demyelinating polyneuropathy (CIDP)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic inflammatory demyelinating polyneuropathy (CIDP)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic inflammatory demyelinating polyneuropathy (CIDP)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
